CAT 2054

Drug Profile

CAT 2054

Alternative Names: CAT-2054; Eicosapentaenoic acid-niacin conjugate (CAT 2054); Niacin-eicosapentaenoic acid conjugate (CAT 2054)

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Antihyperlipidaemics; Eicosanoids; Nicotinic-acids; Omega 3 fatty acids; Peripheral vasodilators; Small molecules; Vitamins
  • Mechanism of Action Sterol regulatory element binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypercholesterolaemia

Most Recent Events

  • 30 Jun 2016 Catabasis completes its phase IIa trial for Hypercholesterolaemia in USA (NCT02608697)
  • 07 Jun 2016 Efficacy, adverse events and pharmacodynamics data from a phase IIa trial in Hypercholesterolaemia released by Catabasis Pharmaceuticals
  • 02 Mar 2016 Catabasis completes enrolment in its phase IIa trial for Hypercholesterolaemia in USA (NCT02608697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top